TechnoDerma Medicines announced the completion of Series A Financing

News

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2021-04-14

Source: Viva Biotech

[Abstract]:This round of financing will be mainly used to advance the clinical trials and follow-up R&D.

Shanghai, China——Recently, Jiaxing TechnoDerma Medicines Inc., a biotech start-up invested and incubated by Viva BioInnovator, which focused on the R&D of innovative drugs for skin indications, announced the completion of tens of millions of yuan in Series A financing. The financing funds will be used to advance the clinical trials and follow-up R&D, and strengthen the development of the R&D team.

Previous Page：VivaVision Completed 300 Million RMB Series D Financing Next Page：Phenomic AI：the biotech business harnessing the power of AI

Back

Media contact: vivapr@vivabiotech.com